Format

Send to

Choose Destination
Leuk Res. 2014 Jan;38(1):23-8. doi: 10.1016/j.leukres.2013.08.015. Epub 2013 Sep 5.

The clinical significance of cereblon expression in multiple myeloma.

Author information

1
Cancer Care and Hematology, University of Colorado Health, Fort Collins, CO, USA. Electronic address: Steven.Schuster@UCHealth.org.
2
Division of Hematology, Mayo Clinic in Arizona, Scottsdale, AZ, USA.
3
Division of Hematology, Mayo Clinic, Rochester, MN, USA.
4
Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, MN, USA.
5
Department of Hematology, University of Arkansas, Little Rock, AR, USA.

Abstract

Cereblon (CRBN) mediates immunomodulatory drug (IMiD) action in multiple myeloma (MM). We demonstrate here that no patient with very low CRBN expression responded to IMiD plus dexamethasone therapy. In 53 refractory MM patients treated with pomalidomide and dexamethasone, CRBN levels predict for decreased response rates and significant differences in PFS (3.0 vs. 8.9 months, p<0.001) and OS (9.1 vs. 27.2 months, p=0.01) (lowest quartile vs. highest three quartiles). While higher CRBN levels can serve as a surrogate for low risk disease, our study demonstrates that low CRBN expression can predict resistance to IMiD monotherapy and is a predictive biomarker for survival outcomes.

KEYWORDS:

Biological markers; Cereblon; Gene expression profiling; Immunomodulatory drugs; Multiple myeloma

Comment in

PMID:
24129344
PMCID:
PMC3905958
DOI:
10.1016/j.leukres.2013.08.015
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center